- Home
- RLAY vs BDN Comparison
RLAY vs BDN Comparison
Compare RLAY & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- BDN
- Stock Information
- Founded
- RLAY 2015
- BDN 1986
- Country
- RLAY United States
- BDN United States
- Employees
- RLAY N/A
- BDN N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- BDN Real Estate Investment Trusts
- Sector
- RLAY Health Care
- BDN Real Estate
- Exchange
- RLAY Nasdaq
- BDN Nasdaq
- Market Cap
- RLAY 1.0B
- BDN 693.1M
- IPO Year
- RLAY 2020
- BDN N/A
- Fundamental
- Price
- RLAY $6.15
- BDN $3.39
- Analyst Decision
- RLAY Strong Buy
- BDN Hold
- Analyst Count
- RLAY 9
- BDN 2
- Target Price
- RLAY $16.00
- BDN $4.50
- AVG Volume (30 Days)
- RLAY 2.2M
- BDN 3.1M
- Earning Date
- RLAY 11-06-2025
- BDN 10-22-2025
- Dividend Yield
- RLAY N/A
- BDN 9.44%
- EPS Growth
- RLAY N/A
- BDN N/A
- EPS
- RLAY N/A
- BDN N/A
- Revenue
- RLAY $8,355,000.00
- BDN $404,321,000.00
- Revenue This Year
- RLAY $27.30
- BDN $58.99
- Revenue Next Year
- RLAY $7.43
- BDN $0.33
- P/E Ratio
- RLAY N/A
- BDN N/A
- Revenue Growth
- RLAY N/A
- BDN 31.73
- 52 Week Low
- RLAY $1.78
- BDN $3.23
- 52 Week High
- RLAY $7.64
- BDN $5.90
- Technical
- Relative Strength Index (RSI)
- RLAY 45.56
- BDN 34.76
- Support Level
- RLAY $6.64
- BDN $3.23
- Resistance Level
- RLAY $7.42
- BDN $3.89
- Average True Range (ATR)
- RLAY 0.44
- BDN 0.12
- MACD
- RLAY -0.19
- BDN -0.01
- Stochastic Oscillator
- RLAY 8.31
- BDN 23.48
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.